Source link : https://www.newshealth.biz/health-news/mdma-is-off-the-table-so-whats-next-for-ptsd/
It has been 24 years since a pharmaceutical was last approved for posttraumatic stress disorder (PTSD). The condition is notoriously difficult to treat, with up to 40% patients finding no relief from symptoms through psychotherapy or current medications. Many clinicians, advocates, and patients had pinned their hopes on the psychedelic drug midomafetamine with assisted therapy […]
Author : News Health
Publish date : 2024-10-17 14:08:27
Copyright for syndicated content belongs to the linked Source.
